secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-10-09T21:15:50+00:00
Accession:  0001437749-26-032455
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Moleculin shareholders approve reverse split authority up to 1-for-20; supermajority removal fails
--------------------------------------------------------------------------------

- Shareholders approved board authority for a reverse stock split at a ratio of 1-for-2 to 1-for-20, exercisable before the one-year anniversary of the Oct. 9, 2026 annual meeting.
- Amendment to eliminate supermajority charter-voting requirements failed, falling short of the required two-thirds of outstanding shares (2,828,497 for, 901,488 against).
- Stockholders approved an amendment to the 2024 Stock Plan adding 3,861,894 shares; the 8-K states 3,875,999 shares total authorized for issuance.
- Re-elected directors Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco and Elizabeth A. Cermak; Grant Thornton LLP ratified as auditor for fiscal 2026 and say-on-pay passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926032455/0001437749-26-032455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926032455/mbrx20261009_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer